Intronbio Presents SAL200 Clinical Trial Results at International Conference

[Asia Economy Reporter Hyungsoo Park] Intronbio announced on the 28th that it will present the results of the world's first multiple-dose clinical study of SAL200, an endolysin drug, at the international infectious disease conference IDWeek 2021.

The presentation covers the Phase 1b MAD (multiple ascending dose) study and will be delivered at IDWeek 2021, held from the 29th of this month to the 3rd of next month.

IDWeek is the largest academic conference in the field of infectious diseases worldwide. It is a joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

At the conference, Lysovant Sciences, Inc., a subsidiary of Roivant that has adopted SAL200 technology, will present. In addition to the clinical trial results of SAL200, other experimental results will also be disclosed.

Seoyeon Jeon, Director of the Biotechnology Research Center at Intronbio, stated, "After technology transfer, we have conducted additional follow-up studies on SAL200 and have continuously presented excellent results to the academic community," adding, "This demonstrates the superior drug characteristics of SAL200."

Intronbio CEO Kyungwon Yoon explained, "Lysovant is a global clinical specialist company with professional capabilities," and "They are making significant investments for the successful commercialization of SAL200."

He continued, "Not only Lysovant but also many global clinical experts from Roivant are well preparing for the clinical trials in the United States," emphasizing, "Since Intronbio is also actively supporting them, I am confident of success."